Breast cancer
RecruitingStudy on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients
Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients
- Disease:Breast cancer
- Substances:AbemaciclibAnastrozole+8
Poland- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
- Sponsor:Medica Scientia Innovation Research S.L.



